STOCK TITAN
  1. Home
  2. Sec-filings
  3. SYRE
  4. [Form 4] Spyre Therapeutics, Inc. Insider Trading Activity

Spyre Therapeutics (SYRE) CEO trades 15,000 shares under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. CEO Cameron Turtle sold a total of 15,000 shares of common stock on August 3, 2026 in five open-market transactions under a Rule 10b5-1 trading plan adopted on June 20, 2025, at weighted average prices between $93.97 and $97.46 per share.

The sales occurred across trade ranges from $93.42 to $97.47 per share. The reported holdings include 58,108 shares that vest in monthly installments through November 2026, subject to continued service.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Turtle Cameron
Role Chief Executive Officer
Sold 15,000 shs ($1.43M)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 800 $93.97 $75K
Sale Common Stock F1, F4, F3 7,157 $95.10 $681K
Sale Common Stock F1, F5, F3 5,635 $95.93 $541K
Sale Common Stock F1, F6, F3 1,392 $96.82 $135K
Sale Common Stock F1, F7, F3 16 $97.46 $2K
Holdings After Transaction: Common Stock — 567,540 shares (Direct)
Footnotes (7)
  1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3. Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
  4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.45 to $96.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.45 to $97.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  7. F7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.46 to $97.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Total shares sold 15,000 shares Aggregate common stock sold by CEO Cameron Turtle on August 3, 2026
Tranche 1 sale 800 shares at $93.97 First reported open-market sale of common stock on August 3, 2026
Tranche 2 sale 7,157 shares at $95.10 Second reported open-market sale of common stock on August 3, 2026
Tranche 3 sale 5,635 shares at $95.93 Third reported open-market sale of common stock on August 3, 2026
Tranche 4 sale 1,392 shares at $96.82 Fourth reported open-market sale of common stock on August 3, 2026
Tranche 5 sale 16 shares at $97.46 Fifth reported open-market sale of common stock on August 3, 2026
Rule 10b5-1 plan adoption date June 20, 2025 Adoption date of the trading plan governing the August 3, 2026 sales
Time-vesting shares 58,108 shares Common stock vesting in monthly installments through November 2026, subject to service
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vest in monthly installments financial
"Includes 58,108 shares of common stock that vest in monthly installments through November 2026..."
common stock financial
"Includes 58,108 shares of common stock that vest in monthly installments through November 2026..."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did Spyre Therapeutics (SYRE) report for August 3, 2026?
Spyre Therapeutics reported that CEO Cameron Turtle sold 15,000 shares of common stock on August 3, 2026 in five open-market trades under a Rule 10b5-1 trading plan adopted on June 20, 2025.

How many Spyre Therapeutics (SYRE) shares did CEO Cameron Turtle sell and at what prices?
Cameron Turtle sold 15,000 shares of SYRE common stock at weighted average prices from $93.97 to $97.46 per share, with individual trade prices ranging between $93.42 and $97.47.

Were the SYRE CEO’s stock sales made under a Rule 10b5-1 plan?
Yes. The filing states the August 3, 2026 sales were executed under a Rule 10b5-1 trading plan adopted on June 20, 2025, indicating the transactions followed a pre-established schedule.

How were the sale prices for the SYRE insider transactions reported?
Each sale’s price is reported as a weighted average price, with footnotes explaining that shares were sold in multiple transactions within specified price ranges, from $93.42 up to $97.47 per share.

What ongoing equity awards does the SYRE CEO have after these sales?
The reported holdings include 58,108 shares of Spyre Therapeutics common stock that vest in monthly installments through November 2026, contingent on Cameron Turtle’s continued service.

How many separate trades did the Spyre Therapeutics (SYRE) CEO execute on August 3, 2026?
The Form 4 lists five separate open-market sale transactions on August 3, 2026, involving share amounts of 800, 7,157, 5,635, 1,392, and 16 shares of common stock.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Turtle Cameron
(Last)(First)(Middle)
221 CRESCENT STREET, BUILDING 23,
SUITE 105
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/03/2026S(1)800D$93.97(2)581,740(3)D
Common Stock08/03/2026S(1)7,157D$95.1(4)574,583(3)D
Common Stock08/03/2026S(1)5,635D$95.93(5)568,948(3)D
Common Stock08/03/2026S(1)1,392D$96.82(6)567,556(3)D
Common Stock08/03/2026S(1)16D$97.46(7)567,540(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
3. Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.45 to $96.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.45 to $97.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.46 to $97.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Remarks:
/s/ Heidy King-Jones, as Attorney-in-Fact08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR